Reliable biomarkers predicting likelihood of therapeutic success to subsequent anti-TNF therapy, would allow utilization of a personalized medicine concept with optimized use of this substance class, providing a substantial benefit for the treated IBD patient (13). The gene discussed is TNF; the disease is inflammatory bowel disease.